-COPY OF PAPER ORIGINALLY FILED

0211-02

3739

- 12					
May Cure		ERTIFICATE OF MAILING			
	spondence is being deposited wit ashington, D.C. 2023 I on this da	h the United States Postal Service a te.	ıs first class r	mail in an	envelope addressed to:
Typed or Printed Name	Teri Muir				
Signature	Lini In	ui		Date	MAR. 14, 2002
INFOR	MATION	Attorney Docket	PALX	-003D	IV
	STATEMENT	First Named Inventor	PREIS	SMAN	I, HOWARD
		Application Number	10/039	,892	w = 3
		Confirmation No.	8727		700
		Filing Date	Octobe	er 26, 2	2001
Address to: Commissioner for Pater	atc.	Group Art Unit	3739		产器图
Washington, D.C. 2023		Examiner Name)0%
		Title: "HIGH PRESS	SURE AP.	PLICA	TOR"

Sir:

This is an Information Disclosure Statement submitted for the Examiner's consideration. A Form PTO-SB/08A listing the references and copies of the cited references accompany this paper. Applicants would appreciate the Examiner's initialing and returning the form to indicate that the references have been reviewed and made of record.

All of the references identified herein were disclosed in parent applications serial number 09/053,108, filed 4/1/1998 and serial number 09/409,934, filed 9/30/1999 and as such, copies thereof are not included pursuant to the provisions of 37 CFR § 1.98(d).

This Information Disclosure Statement is not intended as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one of the above references constitutes prior art to the present application within the meaning of 35 U.S.C.§102.

As applicants have not yet received a first Action on the merits, no fee is believed to be required for filing this Disclosure Statement. If, however, the PTO finds that for some reason a fee is due, our Deposit Account No. 50-0815, Order No. PALX-003DIV may be charged thereon.

Respectfully submitted, BOZICEVIC, FIELD & FRANCIS LLP

Date: 3/14/01

Frank P. Becking

Registration No. 42,309

BOZICEVIC, FIELD & FRANCIS LLP 200 Middlefield Road, Suite 200 Menlo Park, CA 94025

Telephone: (650) 327-3400 Facsimile: (650) 327-3231



COPY OF PAPERS ORIGINALLY FILED



Rlease type a plus sign (+) inside this box ->

PTO/SB/08A (08-00) Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number,

Substitute for form 1449A/PTO

TRADEN

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 4

Complete if Known					
Application Number	10/039,892				
Filing Date	October 26, 2001				
First Named Inventor	Howard Preissman				
Group Art Unit	3739				
Examiner Name	N/A				
Attorney Docket Number	PALX-003DIV				

					U.S. PATENT DOCU	U.S. PATENT DOCUMENTS		
Examin er Initials'	Cite No. ¹	No. Number Kind Code (if known)		Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, columns, lines, Where Relevant Passages or Relevant Figures Appear		
	29,083			Irving	7/10/60	rigores Appear		
	-	3,701	,771		Almen et al.	10/31/72		
		3,750	,667		Pshenichny et al.	8/7/73		
		3,835	,860		Garretson	9/17/74		
		3,882	,858		Klemm	5/13/75		
		3,919	,773		Freeman	11/18/75	-1	
		4,189	,065		Herold	2/19/80	ω _ 7J	
		4,274	,163		Malcom et al.	6/23/81	3 3 13	
		4,288			Anderson et al.	9/8/91	2 1 17	
		4,312	343		LeVeen et al.	1/26/82		
		4,341,	691		Anuta	7/27/82		
		4,364,	921		Speck et al.	12/21/82	ROOM	
	4,373,217			Draenert	2/15/83	-16		
		4,404,	327		Crugnola et al.	9/13/83		
		4,469,	109		Mehl	9/4/84		
		4,554,	686		Baker	11/26/85		
		4,610,	692		Eitenmuller et al.	9/9/86		
		4,637,	931		Schmitz	1/20/87		
		4,653,	489		Tronzo	3/31/87		
		4,670,	800		VonAlbertini	6/2/87		
		4,671,	263		Draenert	6/9/87		
		4,728,	570		Ashman et al.	3/1/88		
		4,791,	150		Braden et al.	12/13/88		
		4,793,	363		Ausherman et al.	12/27/88		
		4,795,4	444		Hasegawa et al.	1/3/89		
		4,798,	596		Muhlbauer	1/17/89		
		4,815,4	454		Dozier Jr.	3/28/89		
		4,837,2	279		Arroyo	6/6/89		

Examiner	Date
Signature	Considered

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.



COPY OF PAPERS ORIGINALLY FILED



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Inder the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Supstitute for form 1449A/PTO

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

2 of 4

С	Complete if Known	-
Application Number	10/039,892	
Filing Date	October 26, 2001	
First Named Inventor	Howard Preissman	
Group Art Unit	3739	
Examiner Name	N/A	
Attorney Docket Number	PALX-003DIV	

4,838,282 Strasser et al. 6/13/89 4,900,546 Posey-Dowly et al. 2/13/90 4,921,479 Grayzel 5/1/90 4,929,238 Baum 5/29/90 4,966,601 Draenert 10/30/90 4,969,888 Scholten et al. 11/13/90 4,986,814 Burney et al. 1/22/91 5,014,717 Lohrmann 5/14/91 5,015,101 Draenert 5/14/91 5,108,404 Scholten et al. 4/28/92 5,112,354 Sires 5/12/92 5,195,525 Michelson 3/23/93 5,282,861 Kaplan 2/1/94 5,304,586 Hammesfahr et al. 4//9/94 5,336,699 Cooke et al. 8/9/94 5,336,699 Cooke et al. 8/9/94 5,341,816 Allen 8/30/94 5,346,495 Vargas III 9/13/94 5,367,002 Huang et al. 11/22/94 5,372,583 Roberts et al. 12/13/94 5,456,467 Stark 10/10/95 5,476,880 Cooke et al. 9/19/95 5,571,182 Ersek et al. 11/12/96 5,577,182 Ersek et al. 11/12/96 5,557,171 Brown 11/7/97 5,663,730 Hammerslag 8/5/97 5,660,186 Bachir 8/26/97 5,660,186 Scarboough 10/14/97					
4,921,479		4,838,282	Strasser et al.	6/13/89	
4,929,238 Baum 5/29/90 4,966,601 Draenert 10/30/90 4,969,888 Scholten et al. 11/13/90 4,986,814 Burney et al. 1/22/91 5,014,717 Lohrmann 5/14/91 5,014,717 Lohrmann 5/14/91 5,108,404 Scholten et al. 4/28/92 5,112,354 Sires 5/12/92 5,195,525 Michelson 3/23/93 5,282,861 Kaplan 2/1/94 5,304,586 Hammesfahr et al. 4/19/94 5,336,699 Cooke et al. 8/9/94 5,336,699 Cooke et al. 8/9/94 5,341,816 Allen 8/30/94 5,367,002 Huang et al. 11/22/94 5,372,583 Roberts et al. 12/13/94 5,451,406 Lawin et al. 9/19/95 5,456,267 Stark 10/10/95 5,466,267 Stark 10/10/95 5,507,813 Dowd et al. 4/16/96 5,571,182 Ersek et al. 11/12/96 5,574,075 Draenert 11/12/96 5,565,332 Ducheyne et al. 8/19/97 5,665,333 Doucheyne et al. 8/19/97 5,653,332 Ducheyne et al. 8/19/97 5,660,186 Bachir 8/26/97		4,900,546	Posey-Dowty et al.	2/13/90	
		4,921,479	Grayzel	5/1/90	
4,969,888 Scholten et al. 11/13/90 4,986,814 Burney et al. 1/22/91 5,014,717 Lohrmann 5/14/91 5,015,101 Draenert 5/14/91 5,108,404 Scholten et al. 4/28/92 5,112,354 Sires 5/12/92 5,195,525 Michelson 3/23/93 5,282,861 Kaplan 2/1/94 5,304,586 Hammesfahr et al. 4/19/94 5,336,699 Cooke et al. 8/9/94 5,341,816 Allen 8/30/94 5,346,495 Vargas III 9/13/94 5,372,583 Roberts et al. 11/22/94 5,372,583 Roberts et al. 12/13/94 5,451,406 Lawin et al. 9/19/95 5,456,267 Stark 10/10/95 5,476,880 Cooke et al. 10/19/95 5,577,981 Dowd et al. 4/16/96 5,527,298 Vance et al. 6/18/96 5,571,182 Ersek et al. 11/12/96 5,571,182 Ersek et al. 11/12/96 5,571,182 Ersek et al. 11/19/96 5,571,182 Ersek et al. 11/19/97 5,653,730 Hammerslag 8/5/97 5,660,186 Bachir 8/26/97		4,929,238	Baum	5/29/90	
4,986,814 Burney et al. 1/22/91 5,014,717 Lohrmann 5/14/91 5,015,101 Draenert 5/14/91 5,108,404 Scholten et al. 4/28/92 5,112,354 Sires 5/12/92 5,195,525 Michelson 3/23/93 5,282,861 Kaplan 2/1/94 5,304,586 Hammesfahr et al. 4/19/94 5,336,693 Ersek et al. 8/9/94 5,336,699 Cooke et al. 8/9/94 5,341,816 Allen 8/30/94 5,346,495 Vargas III 9/13/94 5,367,002 Huang et al. 11/22/94 5,372,583 Roberts et al. 12/13/94 5,451,406 Lawin et al. 9/19/95 5,456,267 Stark 10/10/95 5,476,880 Cooke et al. 10/19/95 5,507,813 Dowd et al. 4/16/96 5,571,182 Ersek et al. 11/5/96 5,574,075 Draenert 11/12/96 5,591,171 Brown 17/197 5,658,332 Ducheyne et al. 8/19		4,966,601	Draenert	10/30/90	
5,014,717 Lohrmann 5/14/91 5,015,101 Draenert 5/14/91 5,108,404 Scholten et al. 4/28/92 5,112,354 Sires 5/12/92 5,195,525 Michelson 3/23/93 5,282,861 Kaplan 2/1/94 5,304,586 Hammesfahr et al. 4/19/94 5,336,263 Ersek et al. 8/9/94 5,336,699 Cooke et al. 8/9/94 5,341,816 Allen 8/30/94 5,367,002 Huang et al. 11/22/94 5,372,583 Roberts et al. 12/13/94 5,451,406 Lawin et al. 9/19/95 5,466,267 Stark 10/10/95 5,507,813 Dowd et al. 4/16/96 5,527,298 Vance et al. 6/18/96 5,571,182 Ersek et al. 11/12/96 5,591,171 Brown 11/7/97 5,653,730 Hammerslag 8/5/97 5,660,186 Bachir 8/26/97		4,969,888	Scholten et al.	11/13/90	
5,015,101 Draenert 5/14/91 5,108,404 Scholten et al. 4/28/92 5,112,354 Sires 5/12/92 5,195,525 Michelson 3/23/93 5,282,861 Kaplan 2/1/94 5,304,586 Hammesfahr et al. 4/19/94 5,336,263 Ersek et al. 8/9/94 5,336,699 Cooke et al. 8/9/94 5,341,816 Allen 8/30/94 5,346,495 Vargas III 9/13/94 5,367,002 Huang et al. 11/22/94 5,372,583 Roberts et al. 12/13/94 5,456,267 Stark 10/10/95 5,476,880 Cooke et al. 10/19/95 5,507,813 Dowd et al. 4/16/96 5,571,182 Ersek et al. 11/5/96 5,574,075 Draenert 11/12/96 5,591,171 Brown 1/7/97 5,653,730 Hammerslag 8/5/97 5,660,186 Bachir 8/26/97		4,986,814	Burney et al.	1/22/91	
5,282,861 Kaplan 2/1/94 5,304,586 Hammesfahr et al. 4/19/94 5,336,263 Ersek et al. 8/9/94 5,336,699 Cooke et al. 8/9/94 5,341,816 Allen 8/30/94 5,346,495 Vargas III 9/13/94 5,367,002 Huang et al. 11/22/94 5,372,583 Roberts et al. 12/13/94 5,451,406 Lawin et al. 9/19/95 5,456,267 Stark 10/10/95 5,476,880 Cooke et al. 10/19/95 5,507,813 Dowd et al. 4/16/96 5,527,298 Vance et al. 6/18/96 5,571,182 Ersek et al. 11/5/96 5,574,075 Draenert 11/12/96 5,591,171 Brown 1/7/97 5,653,730 Hammerslag 8/5/97 5,660,186 Bachir 8/26/97		5,014,717	Lohrmann	5/14/91	6
5,282,861 Kaplan 2/1/94 5,304,586 Hammesfahr et al. 4/19/94 5,336,263 Ersek et al. 8/9/94 5,336,699 Cooke et al. 8/9/94 5,341,816 Allen 8/30/94 5,346,495 Vargas III 9/13/94 5,367,002 Huang et al. 11/22/94 5,372,583 Roberts et al. 12/13/94 5,451,406 Lawin et al. 9/19/95 5,456,267 Stark 10/10/95 5,476,880 Cooke et al. 10/19/95 5,507,813 Dowd et al. 4/16/96 5,527,298 Vance et al. 6/18/96 5,571,182 Ersek et al. 11/5/96 5,574,075 Draenert 11/12/96 5,591,171 Brown 1/7/97 5,653,730 Hammerslag 8/5/97 5,660,186 Bachir 8/26/97		5,015,101	Draenert	5/14/91	2 7 77
5,282,861 Kaplan 2/1/94 5,304,586 Hammesfahr et al. 4/19/94 5,336,263 Ersek et al. 8/9/94 5,336,699 Cooke et al. 8/9/94 5,341,816 Allen 8/30/94 5,346,495 Vargas III 9/13/94 5,367,002 Huang et al. 11/22/94 5,372,583 Roberts et al. 12/13/94 5,451,406 Lawin et al. 9/19/95 5,456,267 Stark 10/10/95 5,476,880 Cooke et al. 10/19/95 5,507,813 Dowd et al. 4/16/96 5,527,298 Vance et al. 6/18/96 5,571,182 Ersek et al. 11/5/96 5,574,075 Draenert 11/12/96 5,591,171 Brown 1/7/97 5,653,730 Hammerslag 8/5/97 5,660,186 Bachir 8/26/97		5,108,404	Scholten et al.	4/28/92	3 ? 9
5,282,861 Kaplan 2/1/94 5,304,586 Hammesfahr et al. 4/19/94 5,336,263 Ersek et al. 8/9/94 5,336,699 Cooke et al. 8/9/94 5,341,816 Allen 8/30/94 5,346,495 Vargas III 9/13/94 5,367,002 Huang et al. 11/22/94 5,372,583 Roberts et al. 12/13/94 5,451,406 Lawin et al. 9/19/95 5,456,267 Stark 10/10/95 5,476,880 Cooke et al. 10/19/95 5,507,813 Dowd et al. 4/16/96 5,527,298 Vance et al. 6/18/96 5,571,182 Ersek et al. 11/5/96 5,574,075 Draenert 11/12/96 5,591,171 Brown 1/7/97 5,653,730 Hammerslag 8/5/97 5,660,186 Bachir 8/26/97		5,112,354	Sires	5/12/92	
5,282,861 Kaplan 2/1/94 5,304,586 Hammesfahr et al. 4/19/94 5,336,263 Ersek et al. 8/9/94 5,336,699 Cooke et al. 8/9/94 5,341,816 Allen 8/30/94 5,346,495 Vargas III 9/13/94 5,367,002 Huang et al. 11/22/94 5,372,583 Roberts et al. 12/13/94 5,451,406 Lawin et al. 9/19/95 5,456,267 Stark 10/10/95 5,476,880 Cooke et al. 10/19/95 5,507,813 Dowd et al. 4/16/96 5,527,298 Vance et al. 6/18/96 5,571,182 Ersek et al. 11/5/96 5,574,075 Draenert 11/12/96 5,591,171 Brown 1/7/97 5,653,730 Hammerslag 8/5/97 5,660,186 Bachir 8/26/97		5,195,525	Michelson	3/23/93	三 3 四
5,336,263 Ersek et al. 8/9/94 5,336,699 Cooke et al. 8/9/94 5,341,816 Allen 8/30/94 5,346,495 Vargas III 9/13/94 5,367,002 Huang et al. 11/22/94 5,372,583 Roberts et al. 12/13/94 5,451,406 Lawin et al. 9/19/95 5,456,267 Stark 10/10/95 5,476,880 Cooke et al. 10/19/95 5,507,813 Dowd et al. 4/16/96 5,527,298 Vance et al. 6/18/96 5,571,182 Ersek et al. 11/5/96 5,574,075 Draenert 11/12/96 5,591,171 Brown 1/7/97 5,653,730 Hammerslag 8/5/97 5,660,186 Bachir 8/26/97		5,282,861	Kaplan	2/1/94	22 62
5,336,263 Ersek et al. 8/9/94 5,336,699 Cooke et al. 8/9/94 5,341,816 Allen 8/30/94 5,346,495 Vargas III 9/13/94 5,367,002 Huang et al. 11/22/94 5,372,583 Roberts et al. 12/13/94 5,451,406 Lawin et al. 9/19/95 5,456,267 Stark 10/10/95 5,476,880 Cooke et al. 10/19/95 5,507,813 Dowd et al. 4/16/96 5,527,298 Vance et al. 6/18/96 5,571,182 Ersek et al. 11/5/96 5,574,075 Draenert 11/12/96 5,591,171 Brown 1/7/97 5,653,730 Hammerslag 8/5/97 5,660,186 Bachir 8/26/97		5,304,586	Hammesfahr et al.	4/19/94	0,
5,341,816 Allen 8/30/94 5,346,495 Vargas III 9/13/94 5,367,002 Huang et al. 11/22/94 5,372,583 Roberts et al. 12/13/94 5,451,406 Lawin et al. 9/19/95 5,456,267 Stark 10/10/95 5,476,880 Cooke et al. 10/19/95 5,507,813 Dowd et al. 4/16/96 5,527,298 Vance et al. 6/18/96 5,571,182 Ersek et al. 11/5/96 5,574,075 Draenert 11/12/96 5,591,171 Brown 1/7/97 5,653,730 Hammerslag 8/5/97 5,658,332 Ducheyne et al. 8/19/97 5,660,186 Bachir 8/26/97		5,336,263	Ersek et al.	8/9/94	
5,346,495 Vargas III 9/13/94 5,367,002 Huang et al. 11/22/94 5,372,583 Roberts et al. 12/13/94 5,451,406 Lawin et al. 9/19/95 5,456,267 Stark 10/10/95 5,476,880 Cooke et al. 10/19/95 5,507,813 Dowd et al. 4/16/96 5,527,298 Vance et al. 6/18/96 5,571,182 Ersek et al. 11/5/96 5,574,075 Draenert 11/12/96 5,591,171 Brown 1/7/97 5,653,730 Hammerslag 8/5/97 5,658,332 Ducheyne et al. 8/19/97 5,660,186 Bachir 8/26/97		5,336,699	Cooke et al.	8/9/94	
5,367,002 Huang et al. 11/22/94 5,372,583 Roberts et al. 12/13/94 5,451,406 Lawin et al. 9/19/95 5,456,267 Stark 10/10/95 5,476,880 Cooke et al. 10/19/95 5,507,813 Dowd et al. 4/16/96 5,527,298 Vance et al. 6/18/96 5,571,182 Ersek et al. 11/5/96 5,574,075 Draenert 11/12/96 5,591,171 Brown 1/7/97 5,653,730 Hammerslag 8/5/97 5,658,332 Ducheyne et al. 8/19/97 5,660,186 Bachir 8/26/97		5,341,816	Allen	8/30/94	
5,372,583 Roberts et al. 12/13/94 5,451,406 Lawin et al. 9/19/95 5,456,267 Stark 10/10/95 5,476,880 Cooke et al. 10/19/95 5,507,813 Dowd et al. 4/16/96 5,527,298 Vance et al. 6/18/96 5,571,182 Ersek et al. 11/5/96 5,574,075 Draenert 11/12/96 5,591,171 Brown 1/7/97 5,653,730 Hammerslag 8/5/97 5,658,332 Ducheyne et al. 8/19/97 5,660,186 Bachir 8/26/97		5,346,495	Vargas III	9/13/94	
5,451,406 Lawin et al. 9/19/95 5,456,267 Stark 10/10/95 5,476,880 Cooke et al. 10/19/95 5,507,813 Dowd et al. 4/16/96 5,527,298 Vance et al. 6/18/96 5,571,182 Ersek et al. 11/5/96 5,574,075 Draenert 11/12/96 5,591,171 Brown 1/7/97 5,653,730 Hammerslag 8/5/97 5,660,186 Bachir 8/26/97		5,367,002	Huang et al.	11/22/94	
5,456,267 Stark 10/10/95 5,476,880 Cooke et al. 10/19/95 5,507,813 Dowd et al. 4/16/96 5,527,298 Vance et al. 6/18/96 5,571,182 Ersek et al. 11/5/96 5,574,075 Draenert 11/12/96 5,591,171 Brown 1/7/97 5,653,730 Hammerslag 8/5/97 5,660,186 Bachir 8/26/97		5,372,583	Roberts et al.	12/13/94	
5,456,267 Stark 10/10/95 5,476,880 Cooke et al. 10/19/95 5,507,813 Dowd et al. 4/16/96 5,527,298 Vance et al. 6/18/96 5,571,182 Ersek et al. 11/5/96 5,574,075 Draenert 11/12/96 5,591,171 Brown 1/7/97 5,653,730 Hammerslag 8/5/97 5,660,186 Bachir 8/26/97		5,451,406	Lawin et al.	9/19/95	
5,507,813 Dowd et al. 4/16/96 5,527,298 Vance et al. 6/18/96 5,571,182 Ersek et al. 11/5/96 5,574,075 Draenert 11/12/96 5,591,171 Brown 1/7/97 5,653,730 Hammerslag 8/5/97 5,658,332 Ducheyne et al. 8/19/97 5,660,186 Bachir 8/26/97		5,456,267	Stark		
5,527,298 Vance et al. 6/18/96 5,571,182 Ersek et al. 11/5/96 5,574,075 Draenert 11/12/96 5,591,171 Brown 1/7/97 5,653,730 Hammerslag 8/5/97 5,658,332 Ducheyne et al. 8/19/97 5,660,186 Bachir 8/26/97		5,476,880	Cooke et al.	10/19/95	
5,571,182 Ersek et al. 11/5/96 5,574,075 Draenert 11/12/96 5,591,171 Brown 1/7/97 5,653,730 Hammerslag 8/5/97 5,658,332 Ducheyne et al. 8/19/97 5,660,186 Bachir 8/26/97		5,507,813	Dowd et al.	4/16/96	
5,574,075 Draenert 11/12/96 5,591,171 Brown 1/7/97 5,653,730 Hammerslag 8/5/97 5,658,332 Ducheyne et al. 8/19/97 5,660,186 Bachir 8/26/97		5,527,298	Vance et al.	6/18/96	
5,591,171 Brown 1/7/97 5,653,730 Hammerslag 8/5/97 5,658,332 Ducheyne et al. 8/19/97 5,660,186 Bachir 8/26/97		5,571,182	Ersek et al.	11/5/96	
5,653,730 Hammerslag 8/5/97 5,658,332 Ducheyne et al. 8/19/97 5,660,186 Bachir 8/26/97	· ·	5,574,075	Draenert	11/12/96	
5,658,332 Ducheyne et al. 8/19/97 5,660,186 Bachir 8/26/97		5,591,171	Brown	1/7/97	
5,660,186 Bachir 8/26/97		5,653,730	Hammerslag	8/5/97	
0,20,01		5,658,332	Ducheyne et al.	8/19/97	-
5.676.146 Scarborough 10/14/07		5,660,186	Bachir	8/26/97	
		5,676,146	Scarborough	10/14/97	

Examiner	Date
Signature	Date
Signature	Considered
AFVALUED 1 W 115 4	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.



COPY OF PAPERS ORIGINALLY FILED



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

der the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

3

(use as many sheets as necessary)

of

4

Application Number 10/039,892

Filing Date October 26, 2001

First Named Inventor Howard Preissman

Group Art Unit 3739

Examiner Name N/A

Attorney Docket Number PALX-003DIV

5,681,872	Erbe	10/28/97	
5,788,702	Draenart	8/4/98	•
5,792,478	Lawin et al.	8/11/98	
5,795,922	Demian et al.	8/18/98	
6,080,801	Draenart	6/27/00	

		FC	REIGN PATENT DOCUME	NTS	
Examiner Initials	Cite No.1	Foreign Patent Documents Office ³ Number ⁴ Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		DE 34 43 167 A1	Germany	6/5/86	EC 178 170
		DE 42 19 563 A1	Germany	12/16/93	-3 -3
		EP 0261182 A1	Europe	3/30/88	1 13 13
		WO 92/04924 A1	WIPO	4/2/92	RO
		WO 97/04657 A1	WIPO	2/13/97	ON NO
		WO 99/02214 A1	WIPO	1/21/99	
		WO 99/49819 A1	WIPO	10/7/99	

		OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	_	Convery et al. (1975). "The relative safety of polymethylmethacrylate," J. of Bone and Joint Surg, 57-A(1):57:64.	
		Cotten et al. (1996). "Preoperative percutaneour injection of methyl methacylate and N-butyl cyanoacrylate in vertebral hemangiomas," Am. J. Neuroradiol 17:137-142.	
		Cybulski. (1989) "Methods of surgical stabilization for metastatic disease of the spine," Neurosurgery 25(2):240-252.	
		Deramond et al. (1990) "Percutaneous vertebroplasty with methyl-methacrylate: technique, method, results," Radiology 117(supp.):352.	

xaminer	Date
Signature	Considered

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.



COPY OF PAPERS ORIGINALLY FILED



PTO/SB/08A (08-00) Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE and U.S. Department of the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

(1882 - 87. TO	er the Paperwork Reduction Act or	1995	no persons are rec	quired to respond to a collection of it	nformation unless it contains a valid OMB control number.
Substitute	e for form 1449A/PTO			Complete if Known	
				Application Number	10/039,892
	INFORMATION DISCL			Filing Date	October 26, 2001
ŀ	STATEMENT BY APP	LIC	ANT	First Named Inventor	Howard Preissman
				Group Art Unit	3739
			(y)	Examiner Name	N/A
Sheet	4	of	4	Attorney Docket Number	PALX-003DIV

Dierks et al. (1992) "Treatment of an infected mandibular graft using tobramycin-impregnated methylmethacrylate beads: Report of a case," J. Oral Maxillofac Surg 50:1243-1245.
Galibert et al. (1987). "Note preliminaire sur le traitement des angiomes vertebraux par vertebroplastie acrylique percutanee," Neurochirurgie 33:166-168. (Partial summary translation included.)
Goode and Reynolds. (1992). "Tobramycin-impergnated methylethacrylate for mandible reconstruction," Arch Otolaryngol Head Neck Surg 118:201-204.
Harrington. (1986). "Anterior decompression and stabilization of the spine as a treatment for vertebral collapse and spinal cord compression from metastatic malignancy," Clin. Orthopaedics and Related Research pp. 177-197.
Kaemmerlen et al. (1989). "Veertebroplastie percutanee dans le traitement des metastases," J. Radiol. 70(10):558-562. (Partial summary translation included.)
McLaughlin et al. (1973). "Blood clearance and acute pulmonary toxicity of methylmethacrylate in dogs after simulated arthroplasty and intravenous injection," J. of Bone and Joint Surg 55-A(8):1621-1628.
Nicola and Lins. (1987). "Vertebral hemangioma: Retrograde embolization-Stabilization with methyl methacrylate,: Surg Neurol 27:481-486.
O'Donnel et al. (1994). "Recurrence of giant-cell tumors of the long bones after curettage and packing with cement," J. of Bone and Joint Surg 76-A(12):1827-1833
Persson et al. (1984). "Favourable results of acrylic cementation for giant cell tumors," Acta Orthop Scand 55:209-214.
Phillips et al. (1971). "Cardiovascular effects of implanted crylic bone cement," British Medical Journal 3:460-461.
Shapiro. (1991) "Cranioplasty, vertebral body replacement, and spinal fusion with tobramycin-impregnated methylemethacrylate, Neurosurgery 28(6):789-791.
Stringham et al. (1994). "Percutaneous transpedicular biopsy of the spine," Spine 19(17):1985-1991.
Sundaresen et al. (1985). "Treatment of neoplastic epidural cord compression by vertebral body resection and stabilization,: J Neurosurg. 63:676-684.
Wang et al. (1984). "Safety of anterior cement fixation in the cervical spine: to vivo study of dog spine," So. Medical J. 77(2):178-179.
Weill, A. et al. (1996). "Spinal Metastases: Indications for and Results of Percutaneous" Injection of Acrylic Surgical Cement," Radiology 199(1):241-247.

Evaninas		
Examiner	Date	
Signature	Date	1
Coldinature	Considered	
	Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.